Carbonite: The company beat fourth quarter earnings by 2 cents and slightly raised 2017 estimates. The stock is weak because it lowered first quarter estimates, which pushes earnings out to quarters two through four. Its purchase of Double Take closed a bit later than expected which pushed revenue out. In addition the company will be investing more in sales people and data centers to fuel growth. That said, I will be watching closely for any signs that earnings are pushed out further, which would not be acceptable.

The Chemours Company jumped almost 13% Monday morning on news that it settled an outstanding litigation issue with prior parent DuPont sharing the bill. As I noted in my Feb. 9 buy recommendation, a risk with The Chemours Company stock was the uncertain outcome and unquantified financial payout associated with a lawsuit regarding DuPont’s plant in Ohio. The news today extinguishes the risk of that suit. I am very excited about this news as I considered the legal issue the biggest risk to the stock. Look for more news this Wednesday, Feb. 15 when The Chemours reports earnings before the market opens.

Ichor Systems: Ichor reported a solid quarter last week. Revenue more than doubled, partly due to the company’s purchase of Ajax molds last April. Earnings for the year were $1.32, up 53%. Guidance for the first quarter was better than expected and likely reflects improved spending plans by semiconductor manufacturers like Intel, which announced it would increase its capital expenditures by $2.5 billion dollar in 2017 at its Feb. 9 analyst day.

Jazz Pharmaceuticals: Jazz jumped as analysts grew more excited about data from the company’s phase III trial using its narcolepsy drug for new indications. A phase III trial is the final and most important phase of a drug trial. These results are expected at some point in the first quarter. The company also announced it has enrolled the first patients in an earlier phase trial using its narcolepsy drug for Parkinson’s patients.

Patrick Industries: I sold Patrick this week for a 41% gain. The RV industry has been a tremendous grower for the past year but I think the stocks may be getting ahead of the fundamentals. Competitor LCII (previously known as Drew Industries, a stock I sold out of our portfolio last November), just reported a great quarter but the stock dropped 4%. I’d rather book a fabulous gain than take the risk a possible slowdown in RV growth. For those of you who still own the stock, please note it reports earnings this Thursday before the market opens.

PayPal: Analysts brushed off concerns regarding a subpoena that PayPal disclosed. The company disclosed it had received a subpoena from the Department of Justice regarding a money laundering probe. Analysts noted the company’s increased investment in compliance programs. This is not an investigation regarding PayPal itself but rather money laundering inquiries regarding PayPal users. Separately another analyst speculated that Amazon would start including PayPal as a payment option. The stock is close to the $41 strike on our call option but needs to move up quickly to get the option profitable.

Vulcan Materials reported a profit of 80 cents a share, missing forecasts for 83 cents on revenue of $873 million, below expectations for $914 million. Shares dropped as low as $120 before rebounding a bit. Management noted a marked drop in orders the second half of December which it blamed partly on weather and partly due to customer uncertainty due to the election. I’m keeping Vulcan on the buy list but am reviewing the assumptions that support my $165 target.

We have another busy earnings week on tap. Look for alerts with conference call data for The Chemours Company, Patrick Industries and Impinj.

Tuesday, Feb. 14 – Charles River Labs – before market opens

Wednesday, Feb. 15 – The Chemours Company- before market opens

Thursday, Feb. 16 – Patrick Industries- before market opens

Thursday, Feb. 16 – Impinj- after market closes